Total Revenue from Operations reached INR 6,409.15 Cr in FY 2024-25, representing a growth of 9.6% compared to INR 5,848.91 Cr in the previous year. While specific segment-wise per...

Total revenue grew 29% YoY to INR 1,300 Cr. Product sales crossed INR 1,000 Cr for the first time. Q1 FY25 revenue grew 45% YoY excluding Lynparza, and 8% on a quarter-on-quarter b...

Standalone revenue for Q2 FY26 was INR 974 Cr, a decline of 2.6% YoY. Pediatric vaccines grew by 13% YoY, while the adult vaccine (Shingrix) also saw double-digit growth. General M...

The company delivered sales of INR 319 Cr in Q2 FY26, representing a 3% YoY growth. For the 9-month fiscal year ended March 31, 2025, sales reached INR 918 Cr, up 8% compared to th...

The company operates in a single segment, 'Pharmaceuticals'. In Q1 2020-21, Internal Medicine grew 13%, while Vaccines declined 23% and Hospital revenue fell 41%. Overall revenue f...

The company operates in a single business segment, 'Pharmaceutical Business'. For Q3 2025, revenue was INR 233.9 Cr, representing a 46% YoY growth. For the nine months ended Septem...

The core business (Diabetes insulin, Cardiovascular, CNS, and Oral Anti-diabetes) grew 4% YTD September 2025 and 5% on a quarter-to-quarter basis. Partnership-led revenue grew 2% Y...